A resin supplier’s change to the additive package within the same HDPE commercial grade designation — even if the grade name and MI specification remain unchanged — constitutes a material change for Korean KFDA purposes, because the additive package is part of the resin composition declared in the original container technical file. The correct Korean KFDA treatment depends on the nature of the additive change: if the change is limited to lot-to-lot variation of the same listed antioxidant type and loading (within ±10% of the declared AO quantity) and the resin supplier provides a revised certificate of analysis confirming this, the change may be self-declared as a minor change by the Korean pharmaceutical brand’s QA team. If the additive type changes (e.g. AO-1010 replaced by a different antioxidant), a new antioxidant is added, or the AO loading changes by more than ±10% of the declared amount — this is a major change requiring Korean KFDA notification and typically a new Korean Pharmacopoeia extractables test at minimum, and potentially a new chemical compatibility study if the additive change is assessed to affect the extractable profile in contact with the pharmaceutical formulation. Korean pharmaceutical IBM producers should require their HDPE resin supplier to provide formal written notification of all additive package changes at least 90 days before implementation — sufficient time for the Korean pharmaceutical brand’s QA team to assess the KFDA change classification and initiate the appropriate regulatory action before the new resin lot enters production.

The Korean KFDA pharmaceutical container qualification technical file itself can be assembled from data produced at multiple locations — Korea Ever-Power’s dimensional data is produced at its Ansan-si facility in Korea, Korean Pharmacopoeia chemical testing is conducted at a Korean KFDA-accredited laboratory (which may be inside or outside Korea if the laboratory holds relevant Korean KFDA or ICH-recognised accreditation), and the compatibility study is conducted by the Korean pharmaceutical brand at their Korean GMP stability storage facility or at a qualified Korean contract research organisation. The critical requirement is that all testing must use IBM containers produced on the qualified IBM machine at the qualified production site — the production site must be identified in the container technical file, and the Korean KFDA container qualification is specific to that production site. This means that a Korean pharmaceutical brand qualifying an IBM container from a Korean IBM container producer (using a Korea Ever-Power ZQ machine at the Korean producer’s facility) must produce the qualification containers at that Korean IBM producer’s facility — not at Korea Ever-Power’s facility in Ansan-si, unless the Korean pharmaceutical brand’s qualified supplier list includes Korea Ever-Power as a direct primary container manufacturer. Korea Ever-Power’s role in the qualification process is machine supplier — providing the machine, mould set and pre-delivery dimensional documentation — not primary container manufacturer, unless a specific Korean pharmaceutical brand engages Korea Ever-Power directly as their primary container supplier under a separate qualified supplier agreement.

Korean KFDA generic pharmaceutical product registration (제네릭 의약품 품목허가) requires the primary container to be qualified as part of the overall product dossier submission. For generic pharmaceuticals targeting the Korean market where an equivalent innovator pharmaceutical product is already registered with a specific primary container (e.g. an ophthalmic product using a 10 ml HDPE IBM container), the generic applicant must submit primary container qualification data that demonstrates bioequivalent container performance — the same container type (HDPE IBM, 10 ml), same closure system (same dropper cap GPI thread), and extractables / leachables data confirming no new or elevated leachable compounds versus the reference listed drug (RLD) container. In practice, Korean generic pharmaceutical applicants do not need to reproduce the full RLD container qualification — they need to demonstrate that their chosen IBM container meets the same Korean KFDA standards as the RLD container, using a qualified Korean IBM container producer and a complete CTF. Korea Ever-Power’s pre-delivery documentation package serves Korean generic pharmaceutical applicants as efficiently as it serves innovator pharmaceutical brands — the cavity-by-cavity dimensional report, machine certification and container drawing are identical in their utility for the Korean KFDA generic product dossier submission as for an innovator NDA submission. Korean generic pharmaceutical projects using Korea Ever-Power IBM containers and the standard GMP documentation package have a typical generic Korean KFDA dossier preparation timeline of 8–14 weeks from first IBM production sample to complete pharmaceutical dossier packaging section, when the compatibility study is the only critical path activity.

If one cavity in a 24-cavity IBM mould set produces dimensions outside the specification in the qualification dimensional report, the qualification cannot proceed until that cavity is brought within specification — because the Korean KFDA pharmaceutical container qualification requires all cavities to be simultaneously within specification, not a statistical sample fraction. The correct sequence is: (1) Identify the out-of-specification cavity by cavity number from the dimensional report. (2) Determine the root cause: hot runner gate imbalance (most common — produces one cavity systematically underweight, with low neck OD), cavity insert dimensional error (requires insert remachining or replacement), or core rod wear at the out-of-specification cavity (requires core rod inspection and replacement if OD is below nominal). (3) Implement corrective action on the specific cavity: gate insert adjustment (for flow imbalance), cavity insert replacement (for dimensional error), or core rod replacement (for wear). (4) Repeat the cavity-by-cavity dimensional qualification run — 500 consecutive production cycles across all 24 cavities — confirming all 24 cavities are simultaneously within specification. (5) Submit the corrected dimensional report as the qualification report. The Korean pharmaceutical brand’s QA team should be notified of the out-of-specification cavity finding and the corrective action taken — this forms part of the qualification deviation management documentation in the Korean GMP quality system. Korea Ever-Power’s mould engineering team provides root cause analysis and corrective action support for out-of-specification cavity findings as a post-delivery service included in the standard pharmaceutical IBM mould warranty.